Patents by Inventor Sunoh Kim

Sunoh Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEK293 cell line for activity studies and HTS system of ?T-type Ca channel
    Patent number: 6984521
    Abstract: There is provided a cell line that is prepared by transforming HEK293 cell with a human Kir2.1 gene using a retrovirus expression system, wherein the HEK293 expresses a stable ?1G T-type calcium channel. The cell line responds sensitively to KCl and forms an appropriate level of the membrane voltage so that the cell signaling pathway may be investigated by the molecular biological and biochemical studies.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: January 10, 2006
    Assignee: Korea Institute of Science and Technology
    Inventors: Ye Sun Han, Hyewhon Rhim, Taehyun Kim, Sunoh Kim, Dae-sik Lim, Juhyun Choi
  • HEK293 cell line for activity studies and HTS system of alpha1G T-type Ca2+ channel
    Publication number: 20050130298
    Abstract: There is provided a cell line that is prepared by transforming HEK293 cell with a human Kir2.1 gene using a retrovirus expression system, wherein the HEK293 expresses a stable ?1G T-type calcium channel. The cell line responds sensitively to KCl and forms an appropriate level of the membrane voltage so that the cell signaling pathway may be investigated by the molecular biological and biochemical studies.
    Type: Application
    Filed: May 28, 2004
    Publication date: June 16, 2005
    Inventors: Ye Sun Han, Hyewhon Rhim, Taehyun Kim, Sunoh Kim, Dae-sik Lim, Juhyun Choi
  • Composition for inhibiting glutamate-mediated neurotoxicity comprising ginsenoside Rg3 or ginsenoside Rh2
    Publication number: 20040247703
    Abstract: Disclosed is a composition for inhibiting glutamate-mediated neurotoxicity comprising 20(S)-ginsenoside Rg3, 20(S)-ginsenoside Rh2 or the mixture of 20(S)-ginsenoside Rg3 and 20(S)-ginsenoside Rh2. The composition of the present invention has an excellent neurotoxicity inhibition effect or nerve cell protection effect. Accordingly, it can be effectively used for treating nervous diseases including cerebral trauma, cerebral apoplexy, cerebral hemorrhage; epilepsy occurred by excessive activation of glutamate receptors; or Huntington's disease.
    Type: Application
    Filed: October 27, 2003
    Publication date: December 9, 2004
    Inventors: Hyewhon Rhim, Sunoh Kim